[{"address1": "210 East Grand Avenue", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 457 2700", "website": "https://www.allogene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 232, "companyOfficers": [{"maxAge": 1, "name": "Dr. Arie S. Belldegrun F.A.C.S., M.D.", "age": 74, "title": "Co-Founder & Executive Chairman", "yearBorn": 1949, "fiscalYear": 2023, "totalPay": 649097, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David D. Chang M.D., Ph.D.", "age": 63, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 994595, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joshua A. Kazam", "age": 46, "title": "Co-Founder & Director", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 260500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy L. Moore Ph.D.", "age": 62, "title": "Executive VP & Chief Technical Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 554354, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zachary J. Roberts M.D., Ph.D.", "age": 45, "title": "Executive VP of Research & Development and Chief Medical Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 747390, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Geoffrey M. Parker", "age": 58, "title": "Executive VP & CFO", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Annie  Yoshiyama", "age": 39, "title": "Senior VP, Corporate Controller & Principal Accounting Officer", "yearBorn": 1984, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Earl M. Douglas Esq.", "age": 60, "title": "Senior VP, General Counsel, Compliance Officer & Corporate Secretary", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan R. Lundeen", "age": 57, "title": "Chief People Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Cassiano", "title": "Executive VP, Chief Corporate Affairs & Brand Strategy Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.58, "open": 2.6, "dayLow": 2.49, "dayHigh": 2.64, "regularMarketPreviousClose": 2.58, "regularMarketOpen": 2.6, "regularMarketDayLow": 2.49, "regularMarketDayHigh": 2.64, "beta": 0.829, "forwardPE": -1.7074829, "volume": 1079018, "regularMarketVolume": 1079018, "averageVolume": 2487762, "averageVolume10days": 1684070, "averageDailyVolume10Day": 1684070, "bid": 2.49, "ask": 2.53, "bidSize": 500, "askSize": 2400, "marketCap": 524871104, "fiftyTwoWeekLow": 2.01, "fiftyTwoWeekHigh": 5.78, "priceToSalesTrailing12Months": 8074.94, "fiftyDayAverage": 2.6148, "twoHundredDayAverage": 3.21825, "currency": "USD", "enterpriseValue": 189089712, "floatShares": 152097261, "sharesOutstanding": 209112000, "sharesShort": 39229292, "sharesShortPriorMonth": 43225799, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.1876, "heldPercentInsiders": 0.17479, "heldPercentInstitutions": 0.80719, "shortRatio": 16.41, "shortPercentOfFloat": 0.2641, "impliedSharesOutstanding": 211496992, "bookValue": 2.464, "priceToBook": 1.0186689, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -279423008, "trailingEps": -1.59, "forwardEps": -1.47, "pegRatio": -1.74, "enterpriseToRevenue": 2909.072, "enterpriseToEbitda": -0.737, "52WeekChange": -0.35500002, "SandP52WeekChange": 0.24014747, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ALLO", "underlyingSymbol": "ALLO", "shortName": "Allogene Therapeutics, Inc.", "longName": "Allogene Therapeutics, Inc.", "firstTradeDateEpochUtc": 1539264600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "074a6d28-e148-3d16-a323-524e6da42340", "messageBoardId": "finmb_558022022", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.51, "targetHighPrice": 14.0, "targetLowPrice": 4.5, "targetMeanPrice": 9.59, "targetMedianPrice": 9.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 12, "totalCash": 444628000, "totalCashPerShare": 2.126, "ebitda": -256558000, "totalDebt": 94210000, "quickRatio": 11.972, "currentRatio": 12.254, "totalRevenue": 65000, "debtToEquity": 18.292, "returnOnAssets": -0.23875, "returnOnEquity": -0.4911, "freeCashflow": -119749752, "operatingCashflow": -228724000, "operatingMargins": -4166.246, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]